MONMOUTH JUNCTION, N.J.–(BUSINESS WIRE)–Tris Pharma, Inc., a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder, pain, addiction and neurological disorders, today announced the appointment of Michael Magee as vice president, quality and compliance.
“Michael joins Tris Pharma at an incredibly exciting time in which we have an established portfolio of ADHD medications and a diverse pipeline of late-stage assets, and where his proven track record in the pharmaceutical industry will play a key role in further enhancing our ongoing quality assurance and compliance initiatives,” said Ketan Mehta, founder and CEO at Tris Pharma. “With Michael on board, we are well-positioned to navigate our growth and continue delivering on our mission to optimize patient outcomes through differentiated therapeutic approaches.”
Mr. Magee will lead and further strengthen Tris Pharma’s continued development and management of quality and compliance operations via the current Good Manufacturing Practices (cGMP) Compliance function of the organization. His responsibilities will include ensuring adherence to, and compliance with, established company quality policies, practices, and standard operating procedures and federal regulations, directing the quality of materials purchased, processed, manufactured and/or distributed by the company, and overseeing and ensuring compliance with all appropriate regulatory agencies.
“I am excited to join the Tris Pharma team and partner across the organization to drive transformational growth in key areas of the business and optimize outcomes for the patients that we serve,” said Mr. Magee. “My passion for motivating teams to have a strong, organization-wide common purpose and sense of community aligns closely with Tris Pharma’s values. Along with the company’s transformative technology and differentiated products, as well as its drug development, manufacturing and commercial capabilities that Tris Pharma is expanding to reach patients globally, the opportunity to join the company was tremendous.”
Mr. Magee brings more than 25 years of experience to Tris Pharma, most recently serving as senior vice president of quality assurance at SCA Pharmaceuticals where he led the multi-site, quality assurance division for the industry leading 503B outsourcing company. Prior to SCA, Mr. Magee held varying roles of increasing responsibility at Ferring Pharmaceuticals, Windtree Therapeutics and Johnson & Johnson, supporting quality assurance, regulatory compliance, operations, technical services and more across the companies. Mr. Magee received his Bachelor of Science in Chemistry from Moravian University and a Bachelor of Science in Pharmacy from St. Joseph’s University (Philadelphia College of Pharmacy).
“Michael brings a wealth of knowledge and a deep understanding of the regulatory and quality landscape, which will be instrumental in maintaining our unwavering commitment to developing therapeutics of the highest quality across ADHD, pain, addiction and neurological disorders,” said Nicholas Cappuccino, Ph.D., chief quality officer, senior vice president of quality & compliance at Tris Pharma. “I look forward to collaborating with Michael to further elevate our quality assurance and regulatory compliance practices.”
About Tris Pharma
Tris Pharma is a privately held, innovation-driven biopharmaceutical company that is applying its drug development capabilities and proprietary technologies to transform the treatment of ADHD, pain and neurological disorders, including addiction and diseases of the central nervous system. Tris is an established commercial organization with a robust portfolio of best-in-class ADHD products and a promising pipeline of differentiated, near-term drug candidates. More information is available at www.trispharma.com and on LinkedIn @TrisPharma.